16-17 November 2017,
Hotel Djeugua, Yaoundé, Cameroon
Meeting Report December 2017
Biology, Diagnosis and Treatment, Epidemiology and Prevention
Pharmaceuticals 2024, 17(6), 691; https://doi.org/10.3390/ph17060691
Buruli ulcer (BU), a neglected tropical disease (NTD), is an infection of the skin and subcutaneous tissue caused by Mycobacterium ulcerans. The disease has been documented in many South American, Asian, and Western Pacific countries and is widespread throughout much of Africa, especially in West... and Central Africa.
more
Rwanda Guidelines for variation to registered pharmaceutical products.
DHS Working Papers No. 102
Front. Trop. Dis. , 09 May 2023 Sec. Neglected Tropical Diseases Volume 4 - 2023 | https://doi.org/10.3389/fitd.2023.1087003
This research report provides results from the study of living conditions
among people with disabilities in Lesotho. Comparisons are made
between disabled and non-disabled in household level and individual
level. Disability was defined as limitation to perform certain activities that
was measure...d according to the Washington City Group questions.
Results obtained in Lesotho are also compared to those obtained in
earlier studies carried out in Mozambique, Zambia, Namibia, Zimbabwe
and Malawi. The Lesotho study was undertaken in 2009-2010.
more
Paper commissioned for the EFA Global Monitoring Report 2010, Reaching the marginalized
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more